SCHEMBL3528513

SCHEMBL3528513

CCOC(=O)CNC(=O)c1c(O)c(-c2ncco2)cc2nccnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.46
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TP53 P04637 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 4/20 0.35
HSD17B10 Q99714 4/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 3/20 0.34
CASP1 P29466 2/20 0.34
CASP7 P55210 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
POLB P06746 2/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3536799 0.85 EGLN3 (0.62) EGLN3
SCHEMBL3757510 0.85 EGLN3 (0.50) EGLN3ALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL3521075 0.83 EGLN3 (0.52) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL3520286 0.81 EGLN3 (0.57) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL3543886 0.80 EGLN3 (0.48) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL3521107 0.80 EGLN3 (0.44) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL3531139 0.79 EGLN3 (0.46) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL3527939 0.79 EGLN3 (0.50) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL3520565 0.79 EGLN3 (0.50) EGLN3ALDH1A1SMN1; SMN2MAPTTP53
SCHEMBL3528917 0.79 EGLN3 (0.48) EGLN3ALDH1A1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885ALDH1A1 191/4885SMN1; SMN2 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.